Fundraising FoxCalciMedica Subsidiary
La Jolla, US · Delaware corporation · 1 known investors
Find your way into CalciMedica Subsidiary
104 people in our graph can introduce you to the CalciMedica Subsidiary team.
Sign up to see every warm intro you have to CalciMedica Subsidiary
- Paths you didn't know you had: your email and LinkedIn already hold routes to the CalciMedica Subsidiary team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
DG
Daniel GeffkenExecutive
SH
Sudarshan HebbarExecutiveSudarshan Hebbar is an Executive Officer at CalciMedica Subsidiary with over 12 years of medical practice in nephrology and critical care, alongside 8+ years of experience in global clinical and product development for diagnostics and therapeutics.
EW
Eric W. RobertsExecutive
KA
Kenneth A. StaudermanNamed on SEC filing
MJ
Michael J. DunnNamed on SEC filing
Board
AR
A. Rachel LehenyBoard director
BG
Brian GallagherBoard director
VG
Vikas GoyalBoard director
JM
John McDonaldBoard director
PM
TW
Timothy WollaegerBoard directorManaging Director Emeritus at Sanderling Ventures
EG
Evelyn GrahamBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$30M disclosed across 3 rounds · 2014–2023
▶$10.3MraisedApr 2023 · 8 investors · BiotechnologyRule 506(b)
▶$10.3MraisedApr 2023 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kenneth A. StaudermanExecutive Officer
- A. Rachel LehenyExecutive Officer, Director
- Daniel GeffkenExecutive Officer
- Sudarshan HebbarExecutive Officer
- Eric W. RobertsExecutive Officer
- Michael J. DunnExecutive Officer, Director
- Offering amount
- $10.3M
- Amount sold
- $10.3M
- First sale
- Mar 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$17.2MraisedMay 2020 · 12 investors · BiotechnologyRule 506(b)
▶$17.2MraisedMay 2020 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert G. McNeilDirector
- Lakmir ChawlaDirector
- A. Rachel LehenyExecutive Officer, Director
- Fred MiddletonDirector
- Robert WilsonDirector
- Eric RobertsExecutive Officer, Director
- Michael DunnExecutive Officer, Director
- Offering amount
- $17.2M
- Amount sold
- $17.2M
- First sale
- May 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.5MraisedApr 2014 · 5 investors · BiotechnologyRule 506(b)
▶$2.5MraisedApr 2014 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Brian GallagherDirector
- Michael DunnExecutive Officer, Director
- Vikas GoyalDirector
- Ken StaudermanExecutive Officer
- John McDonaldDirector
- Peter McWilliamsDirector
- Timothy WollaegerDirector
- Evelyn GrahamDirector
- Offering amount
- $13.1M
- Amount sold
- $2.5M
- First sale
- Apr 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are CalciMedica Subsidiary's investors?
- CalciMedica Subsidiary's investors include Sanderling Ventures.
- How much funding has CalciMedica Subsidiary raised?
- CalciMedica Subsidiary has disclosed $30M raised across 3 rounds.
- Where is CalciMedica Subsidiary headquartered?
- CalciMedica Subsidiary is headquartered in La Jolla, US.